OncoMatch/Clinical Trials/NCT06733038
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Is NCT06733038 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for colorectal cancer.
Treatment: Atezolizumab · Bevacizumab · Irinotecan (CPT-11) · Oxaliplatin · Leucovorin · Fluorouracil (5-FU) — The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
Proficient mismatch repair (pMMR) status in tumour tissue (primary or metastatic), as determined by a local laboratory assay
Excluded: DPYD complete deficiency (homozygous c1679GG, c1905+1AA, c2846TT)
Complete dihydropyrimidine dehydrogenase (DPYD) deficiency (homozygous of the following DPYD polymorphisms: c1679GG, c1905+1AA, c2846TT)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: adjuvant oxaliplatin-containing chemotherapy
Previous adjuvant oxaliplatin-containing chemotherapy
Cannot have received: bevacizumab (bevacizumab)
Previous treatment with bevacizumab
Cannot have received: CD137 agonist
Prior treatment with CD137 agonists
Cannot have received: anti-CTLA-4 therapy
Prior treatment with anti-CTLA4 therapeutic antibody or pathway-targeting agents
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-PD-1 therapeutic antibody or pathway-targeting agents
Cannot have received: anti-PD-L1 therapy
Prior treatment with anti-PD-L1 therapeutic antibody or pathway-targeting agents
Lab requirements
Blood counts
Neutrophils >1.5 x 10^9/L, Platelets >100 x 10^9/L, Hb >9 g/dL
Kidney function
Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5x ULN
Liver function
Total bilirubin ≤1.5x ULN; AST/ALT <2.5x ULN (or <5x ULN with liver metastases); alkaline phosphatase <2.5x ULN (or <5x ULN with liver metastases)
Neutrophils >1.5 x 10^9/L, Platelets >100 x 10^9/L, Hb >9 g/dl; Total bilirubin ≤1.5x ULN; AST/ALT <2.5x ULN (or <5x ULN with liver metastases); alkaline phosphatase <2.5x ULN (or <5x ULN with liver metastases); Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06733038 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adjuvant oxaliplatin-containing chemotherapy, bevacizumab, CD137 agonist disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 wild-type is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 wild-type is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 wild-type is a required biomarker for enrollment.
Are patients with DPYD alterations eligible?
No. DPYD complete deficiency (homozygous c1679GG, c1905+1AA, c2846TT) is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages